Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems

BACKGROUND: Recent work has developed solid drug nanoparticles (SDNs) of efavirenz that have been demonstrated, preclinically, improved oral bioavailability and the potential to enable up to a 50% dose reduction, and is currently being studied in a healthy volunteer clinical trial. Other SDN formula...

Descripción completa

Detalles Bibliográficos
Autores principales: Liptrott, Neill J., Giardiello, Marco, McDonald, Tom O., Rannard, Steve P., Owen, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853089/
https://www.ncbi.nlm.nih.gov/pubmed/29544545
http://dx.doi.org/10.1186/s12951-018-0349-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853089/
https://www.ncbi.nlm.nih.gov/pubmed/29544545
http://dx.doi.org/10.1186/s12951-018-0349-y

Ejemplares similares